FY2025 EPS Estimates for Exelixis Lifted by William Blair

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Research analysts at William Blair raised their FY2025 earnings per share (EPS) estimates for shares of Exelixis in a report issued on Sunday, January 12th. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $1.69 per share for the year, up from their previous forecast of $1.44. The consensus estimate for Exelixis' current full-year earnings is $1.69 per share.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.36 by $0.04. The firm had revenue of $539.50 million for the quarter, compared to analysts' expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business's quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS.

Several other research analysts also recently weighed in on the stock. Brookline Capital Management started coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a "buy" rating for the company. UBS Group began coverage on Exelixis in a research note on Thursday, September 19th. They issued a "neutral" rating and a $30.00 price objective for the company. BMO Capital Markets downgraded Exelixis from an "outperform" rating to a "market perform" rating and lifted their target price for the company from $36.00 to $40.00 in a research note on Friday, December 20th. Truist Financial upped their price target on Exelixis from $38.00 to $42.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Stephens lifted their price objective on shares of Exelixis from $23.00 to $29.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $34.75.

Exelixis Stock Performance

Shares of EXEL traded up $1.62 during mid-day trading on Wednesday, reaching $37.27. The stock had a trading volume of 4,923,204 shares, compared to its average volume of 2,424,554. The business has a fifty day moving average of $34.92 and a 200 day moving average of $29.08. The firm has a market cap of $10.64 billion, a price-to-earnings ratio of 23.89, a PEG ratio of 0.88 and a beta of 0.53. Exelixis has a 12 month low of $20.01 and a 12 month high of $37.31.

Institutional Trading of Exelixis

Institutional investors and hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. lifted its holdings in Exelixis by 15.2% during the 2nd quarter. Victory Capital Management Inc. now owns 116,806 shares of the biotechnology company's stock valued at $2,625,000 after buying an additional 15,368 shares in the last quarter. Federated Hermes Inc. boosted its holdings in shares of Exelixis by 1.0% in the second quarter. Federated Hermes Inc. now owns 227,909 shares of the biotechnology company's stock valued at $5,121,000 after purchasing an additional 2,333 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Exelixis by 3.2% in the second quarter. Massachusetts Financial Services Co. MA now owns 465,048 shares of the biotechnology company's stock worth $10,450,000 after purchasing an additional 14,443 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Exelixis by 7.3% in the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company's stock worth $115,434,000 after purchasing an additional 349,837 shares in the last quarter. Finally, Edgestream Partners L.P. increased its holdings in Exelixis by 128.6% during the 2nd quarter. Edgestream Partners L.P. now owns 114,785 shares of the biotechnology company's stock worth $2,579,000 after purchasing an additional 64,571 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the firm's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the sale, the executive vice president now owns 498,945 shares of the company's stock, valued at $15,666,873. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the company's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at approximately $17,823,783.53. This represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 314,736 shares of company stock worth $10,849,110 over the last three months. 2.85% of the stock is owned by insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.